Michael Shultz

Dr. Michael Shultz


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2012 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
JWJohn D. Wilson
John D. Wilson
WBWilliam C. Broaddus
William C. Broaddus
HDHarry C. Dorn
Harry C. Dorn
PFPanos P. Fatouros
Panos P. Fatouros
CCCharles E. Chalfant
Charles E. Chalfant
MSMichael Shultz
Michael Shultz

10 May 2012 in Applied Sciences
Verified
Journal Article
Open access
PDF file
JLJianqiao Luo
Jianqiao Luo
JWJohn D. Wilson
John D. Wilson
JZJianyuan Zhang
Jianyuan Zhang
JHJerry I. Hirsch
Jerry I. Hirsch
HDHarry C. Dorn
Harry C. Dorn
MSMichael Shultz
Michael Shultz
The current report describes the development of a dual modality tomographic agent for both positron emission tomography and magnetic resonance imaging (PET/MRI). The dual-modality agent in this study was based on a 124I (PET) radiolabeled tri-gadolinium endohedral metallofullerene Gd3N@C80 (MRI) nanoprobe platform. The outer surface of the fullerene cage of the Gd3N@C80 metallofullerenes was surface functionalized with carboxyl and hydroxyl groups (f-Gd3N@C80) using previously developed procedures and subsequently iodinated with 124I to produce 124I-f-Gd3N@C80 nanoprobe. Orthotopic tumor-bearing rats were infused intratumorally by convection-enhanced delivery (CED) with the 124I-f-Gd3N@C80 agent and imaged by MRI or micro PET. The anatomical positioning and distribution of the 124I-f-Gd3N@C80 agent were comparable between the MRI and PET scans. The 124I-f-Gd3N@C80­ dual-agent distribution and infusion site within the tumor was clearly evident in both T1- and T2-weighted MR images. The results demonstrate the successful preparation of a dual-modality imaging agent, 124I-f-Gd3N@C80, which could ultimately be used for simultaneous PET/MR imaging.

1 January 2014 in Nanobiomedicine
Verified
Journal Article
Open access
SGStanley E. Gilliland
Stanley E. Gilliland
ECEverett E. Carpenter
Everett E. Carpenter
MSMichael Shultz
Michael Shultz
Iron oxide nanoparticles have received sustained interest for biomedical applications as synthetic approaches are continually developed for control of nanoparticle properties. However, many approaches focus solely on the material, rather than the complete optimization of synthesis and functionalization together to enhance translation into biological systems. Presented herein is a modified seed growth method designed for obtaining optimal nanoparticle properties and ease of surface functionalization for long term stability. With a one or two addition process, iron oxide nanoparticles were produced in crystallite sizes ranging from 5–15 nm using only benzyl alcohol and an iron precursor. In the functionalization process, concentration variations were required for stabilizing different nanoparticle sizes. Radio frequency induction heating experiments of various crystallite and hydrodynamic sizes verified that the heating efficiency greatly increased while approaching the 15 nm crystallite, and suggested an important role of the overall particle size on heating efficiency. Initial in vitro experiments with the functionalized nanoparticles showed success in providing hyperthermia-induced tumour cell killing without an increase in the temperature of the cell suspension medium. This demonstrates the potential for nanoparticle-based hyperthermia to provide a therapeutic effect while limiting normal tissue damage.